Drug intelligence / Profile preview

R-851

Development stage: Preclinical
Lead developer: Rigel Pharmaceuticals
Modality: Small Molecules, Vaccines & Immunotherapeutics

Overview

R-851 is a small molecule drug developed by Rigel Pharmaceuticals. It acts as an immune response modifier (IRM) and functions by antagonizing interleukin-1 receptor-associated kinase 1 (IRAK1) and inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4). These kinases are key mediators in inflammatory signaling pathways. By targeting IRAK1 and IRAK4, R-851 aims to modulate the immune system's response, particularly in diseases characterized by excessive or dysregulated inflammation. The primary indication under investigation for this compound is rheumatoid arthritis[9][10].

Targets

IRAK1 (Interleukin-1 receptor-associated kinase 1)IRAK4 (Interleukin-1 receptor associated kinase 4)

Beyond the preview

Go deeper on R-851.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-851.

Explore the full profile